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Abstract
Patients with human immunodeficiency virus (HIV) infection have a high risk of developing virally-mediated cancers.
These tumors have several features that could make them vulnerable to immune checkpoint inhibitors (ICIs) including,
but not limited to, increased expression of the CTLA-4 and PD-1 checkpoints on their CD4+ T cells. Even so, HIV-
positive patients are generally excluded from immunotherapy cancer clinical trials due to safety concerns. Hence, only
case series have been published regarding HIV-positive patients with cancer who received ICIs, but these reports of
individuals with a variety of malignancies demonstrate that ICIs have significant activity, exceeding a 65% objective
response rate in Kaposi sarcoma. Furthermore, high-grade immune toxicities occurred in fewer than 10% of treated
patients. The existing data suggest that the underlying biologic mechanisms that mediate development of cancer in
HIV-infected patients should render them susceptible to ICI treatment. Preliminary, albeit limited, clinical experience
indicates that checkpoint blockade is both safe and efficacious in this setting. Additional clinical trials that include HIV-
positive patients with cancer are urgently needed.
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Background
Approximately 15–20% of all cancers can be attributed to a
viral antecedent [1]. This number is amplified by the
immunodeficiency that ensues following human immuno-
deficiency virus (HIV) infection, which creates the im-
munologic milieu conducive to virally-induced oncogenesis.
Examples of virus-induced cancers that propagate in the
setting of HIV-infection and immunodeficiency as well as
immune mechanisms are presented in Table 1 [1–13].
Treatment of HIV-positive cancer patients with traditional
cytotoxic therapy can further exacerbate the already com-
promised immune status as well as create potential
drug-drug interaction with the anti-retroviral therapy
(ART). Hence, the development of novel therapeutics to
expand the anti-neoplastic armamentarium for these pa-
tients is an area of unmet clinical need.
Relationship between HIV and immune checkpoint
molecules
The therapeutic landscape for malignancies is rapidly
evolving with the advent of immune checkpoint inhibi-
tors (ICI), most notably programmed-cell death (lig-
and)-1 (PD-(L)1) and cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) inhibitors. Taking into account that
one of the hallmarks of cancer is its innate ability to
evade the immune system, ICIs may hold transformative
potential owing to their ability to block the suppressive
immune signals produced by tumor cells. These agents
have impressive clinical activity in a broad array of both
solid and hematologic malignancies, including patients
with advanced, refractory disease. To date, seven check-
point inhibitors have been approved by the Food and
Drug Administration (FDA).
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Despite the encouraging results with ICIs in multiple can-
cer types, there is a paucity of data regarding the use of these
agents in patients with HIV-associated malignancies because
these patients are often excluded from clinical trials. Yet, pa-
tients living with HIV have a significantly higher incidence
of cancer including non-Hodgkin lymphoma (~ 21% of can-
cers in HIV-infected people), Kaposi sarcoma (~ 12%), lung
cancer (~ 11%), anal/cervical cancer (~ 10%), as well as other
tumor types such as colorectal (~ 5%), oral/pharyngeal (4%),
and others (NCCN guidelines version 2.2019 AIDS related
Kaposi sarcoma (https://www.nccn.org/professionals/phys-
ician_gls/pdf/kaposi.pdf)(https://www.cancer.gov/about-can-
cer/causes-prevention/risk/infectious-agents/hiv-fact-sheet).
Importantly, patients with rampant HIV infections –
high viral loads in the absence of being on antiretroviral
therapy (ART) – have more expression of CTLA-4 on
their CD4+ T cells when compared to those of healthy
controls (Table 1). Additionally, CTLA-4 levels are in-
versely related to total CD4+ T cell population and dir-
ectly related to HIV viral load and cancer progression
[11]. This same patient population also expresses higher
levels of PD-1 on their CD4+ T cells when compared to
those of healthy controls and this is associated with T
cell exhaustion; further, similar to CTLA-4, PD-1 levels are
also related to HIV viral load and cancer progression [9,
10]. The dual changes in checkpoint cell surface molecules
in patients who are infected with HIV and have cancer
could be exploited in their treatment as is being explored in
a clinical trial of ipilimumab with nivolumab in HIV-associ-
ated solid tumors and lymphoma (NCT02408861) as well
as with pembrolizumab monotherapy in HIV and various
cancers (NCT02595866) (clinicaltrials.gov). HIV evades the
immune response by promoting a state of immune exhaus-
tion, which is similar to the mechanism of how cancers
with upregulated PD-L1/PD-1 axis and/or CTLA-4 expres-
sion elude immune eradication [9, 10, 13]. Therefore, in
theory, ICIs may be beneficial to both the HIV infection
and to cancer.
Virus-induced cancers: immune and mutational landscape
and Neoantigen immunogenicity
Mechanistically, not only do viral infections lead to an in-
crease in expression of the checkpoint cell surface mole-
cules CTLA-4 and PD-1, they also subvert the DNA
damage response within the host cell DNA. Indeed, DNA
viruses (EBV, HHV-8, HPV, etc.) thrive by inserting their
Table 1 Examples of virally associated neoplasms reported in HIV-infected individuals, response to checkpoint blockade and
mechanisms of action as well as mechanisms of action
Cancer Virus Immunotherapy Response Rate
(n/total n) (X%)
Common Side Effects
Anal Cancer Human Papilloma
Virus
Nivolumab 1/2; 50% [2] Anemia, fatigue, rash, hypothyroidism
Burkitt’s lymphoma Epstein Barr Virus Not reported Not reported Not reported
Central nervous system lymphoma Epstein Barr Virus Not reported Not reported Not reported
Cervical Cancer Human Papilloma
Virus
Not reported Not reported Not reported
Hodgkin disease Epstein Barr Virus Nivolumab 1/1; 100% [3] Not reported
Kaposi Sarcoma Human Herpes
Virus-8
Nivolumab or
pembrolizumab
6/9; 67% [4] Fatigue, gastrointestinal discomfort,
pruritis, onycholysis
Kaposi sarcoma-associated herpesvirus
multicentric Castleman disease
Human Herpes
Virus-8
Not reported Not reported Not reported
Merkel Cell Carcinoma Merkel Cell
Polyomavirus
pembrolizumab or
avelumab
2/2; 100% [5, 6] Pneumonitis
Nasopharyngeal Carcinoma Epstein Barr Virus Not reported Not reported Not reported
Penile Cancer Human Papilloma
Virus
Not reported Not reported Not reported
Plasmablastic lymphoma Epstein Barr Virus Not reported Not reported Not reported
Primary effusion lymphoma Human Herpes
Virus-8
Not reported Not reported Not reported
Vulvar Cancer Human Papilloma
Virus
Not reported Not reported Not reported
Biologic mechanisms that are amenable to immune checkpoint blockade associated with cancers in HIV-infected patients
Viral antigens presented by host cells are recognized as foreign [1]
CD4+ T cells in HIV-positive patients have increased expression of the checkpoints CTLA-4 and PD-19,11
The host DNA damage response is impaired in virally-mediated cancers [12]
APOBEC-related mutagenesis is associated with viruses and increases neopeptide hydrophobicity/immunogenicity and correlates with higher levels of PD-L1
expression [7, 8]
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viral genome into the genome of the host cell and subse-
quently hijacking the host cell replicative enzymes [12].
The host DNA damage response that should be activated
in response to the replicating viral DNA or the virally-
stimulated cellular transition from a quiescent to mitotic/
cell cycle state, induced by viruses in order to facilitate
replication, is attenuated by specific proteins expressed by
the DNA tumor viruses. Virally-induced cancers may also
have distinct mutational portfolios and metabolic patterns
that can impact immune response and prognosis. For in-
stance, HPV-associated squamous tumors of the head and
neck may harbor more PIK3CA alterations whereas non-
HPV tumors may have TP53 and cyclin pathway
(CDKN2A and CCND1) alterations. Finally, molecular
editing mechanisms mediated by apolipoprotein B mRNA
editing enzyme catalytic polypeptide-like (APOBEC), a
family of evolutionarily conserved cytidine deaminases in-
volved in DNA and mRNA editing that are upregulated
with viral infection leading to inactivation of viral ge-
nomes, may be relevant. These upregulated enzymes con-
stitute a crucial part of mammalian innate immunity and
are also a major source of mutations in multiple cancer
types. Relevantly, APOBEC-related mutagenesis increases
neoantigen hydrophobicity, a key feature of immunogen-
icity [7]. Cancers with upregulated APOBEC show high
levels of PD-L1 expression that presumably enable the
cancer to evade the immune system and survive in light of
the immunogenic mutation-related peptides induced by
APOBEC [8]. Hence, not surprisingly, PD-1/PD-L1 ICIs
are associated with high response rates in human cancers
that bear APOBEC mutational gene expression patterns [7,
8]. The production of mutations that result in immunogenic
neoantigens or presentation of the viral antigens themselves
may also explain the fact that malignancies such as
virus-related Merkel cell carcinoma and Kaposi sarcoma re-
spond well to ICIs, despite a low tumor mutational burden,
the latter usually being associated with a poor response to
these immunotherapeutics [4, 14, 15].
Activity of immune checkpoint inhibitors among HIV-
positive patients with cancers
There have been only a small number of case series on the
use of ICIs in HIV-positive patients. A recent review that
included all studies published (73 HIV-patients suffering
from several primary tumors treated with either PD-1,
CTLA-4, or both inhibitors) found a response rate of 67%
for Kaposi sarcoma, 30% for non–small cell lung cancer,
and 27% for melanoma; in addition, activity including
complete responses was seen in Merkel cell carcinoma
and in Hodgkin lymphoma [4, 16]. Importantly, only 9%
of individuals reported greater than or equal to grade 3
immune-related toxicities, most of which occurred in pa-
tients who received ipilimumab as part of their regimen
[16]. HIV remained suppressed in 93% of patients with
available data and undetectable viral load and, overall,
CD4+ counts increased [4, 16]. The low numbers of
patients in the dataset reflects the practice of exclusion of
HIV-positive patients from the majority of studies. How-
ever, the activity of ICIs in these reports and their lack of
toxicity suggest that additional trials are needed.
Discussion
Virally-induced cancers suppress the host DNA damage
response machinery and activate enzymes such as APO-
BEC that mutate both the virus and the host genome; in
the latter, the mutations have high hydrophobicity, a
feature associated with neopeptide immunogenicity for
T cells [7]. Viral antigens themselves may also be pre-
sented by the host cells and would presumably be recog-
nized as foreign by the immune system. Upregulation of
PD-L1 may accompany these changes and, since this lig-
and neutralizes the immune system, the tumors can pro-
liferate without immune recognition [7, 8]. Patients with
HIV infection and cancer also demonstrate high expres-
sion of CTLA-4 and PD-1 on their lymphocytes [9, 11].
All of these changes make these tumors hypothetically
vulnerable to ICI treatment. Despite this potential activ-
ity, there have been several concerns that have led to the
exclusion of HIV-infected individuals with cancer from
trials utilizing ICIs. First, ICI-activated lymphocytes may
not work properly in HIV-infected patients due to their
immunodeficiency. However, the absolute decrease in
the number of CD4+ T cells is overcome with the use of
ART, and, in general, in the small number of patients re-
ported, CD4+ counts have tended to increase after ICI
treatment [4, 16]. Another concern might be the poten-
tial increased risk of immune-related complications after
ICIs in patients with a dysregulated immune system.
However, only 9% of patients in a review of 73 treated
individuals developed high-grade immune-related toxic-
ities [16]. Therefore, ICIs for the therapy of advanced-
stage malignancies in patients with HIV infection was
associated with no new safety signals. HIV load
remained suppressed in most patients. Furthermore,
anecdotally, patients with high HIV load can respond
without undue toxicity [4, 16, 17].
There might also be unease regarding potential reactiva-
tion of viruses such as hepatitis B virus, with anecdotal re-
ports of this occurrence in HIV-infected patients treated
with ICIs. However, the risk of hepatitis B virus reactivation
is probably a more serious concern for patients treated
with conventional myelosuppressive chemotherapy. Indeed,
recent guidelines recommend preemptive antiviral therapy
for hepatitis B surface antigen-positive patients undergoing
chemotherapy, irrespective of their baseline viral load or
HIV status. Finally, many drugs can interact with ART.
The interaction between ARTand ICIs will need better def-
inition though, as mentioned, to date, it appears that the
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viral load remained suppressed in the vast majority of indi-
viduals with undetectable viral loads treated ICIs [16].
Overall, various case reports and small series have served
as rationale for the use of ICI in HIV-positive patients with
varying malignancies (Table 1). For instance, favorable re-
sponses without toxicity in HIV-associated Kaposi sarcoma
[4] provide a rationale for future studies.
Conclusion
HIV-infected patients are underrepresented in ICI clinical
trials, despite reports that have clearly demonstrated
promising activity and excellent safety with ICIs among
different advanced malignancies [4, 16]. There are clinical
trials with checkpoint blockade that include HIV-positive
patients with well-controlled disease [18]; however, it is
likely that only a minority of patients on such trials are
actually HIV-positive, and therefore learning about their
outcomes from single trials may be difficult. Additional
studies designed for HIV-positive patients with malignan-
cies are urgently needed. Furthermore, based on the
mechanistic likelihood of ICI response in cancers that
occur in HIV-infected patients and the substantial efficacy
seen in the small series to date, these patients should not
be excluded from immunotherapy clinical trials.
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